Compare AU
Compare F100 vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Ftse 100 ETF (F100) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
F100 | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 44 | 82 |
Median incremental investment | $993.50 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,648.80 | $1,323.41 |
Average age group | > 35 | > 35 |
Key Summary
F100 | CURE | |
|---|---|---|
Strategy | F100.AX was created on 2019-07-12 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to track the price and income performance of the FTSE 100 Index (before fees and expenses). The Index provides exposure to the largest 100 comoanies traded on the London Stock Exchange, based on their market capitalisation. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ASTRAZENECA PLC (8.94 %) SHELL PLC (8.77 %) HSBC HOLDINGS PLC (6.17 %) | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) |
Top 3 industries | Financials (17.65 %) Consumer Staples (17.44 %) Energy (13.29 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United Kingdom of Great Britain and Northern Ireland (95.85 %) Switzerland (2.89 %) United States (0.96 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
F100 | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | FTSE 100 Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $12.48 | $49.94 |
Size | $340.912 million | $38.065 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.01 % | 4.24 % |
Market | ASX | ASX |
First listed date | 16/07/2019 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
F100 | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 44 | 82 |
Median incremental investment | $993.50 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,648.80 | $1,323.41 |
Average age group | > 35 | > 35 |
Pros and Cons
F100 | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
F100 | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |